Evidence over reviews — drugs and supplements sorted by research, track record and real usage in this app.
For a cat with confirmed atrial enlargement (B2), the evidence is clear — top of the cardiac-drug ladder. If your cat is already on it, never skipping doses is the best prevention there is.
An enlarged left atrium lets blood swirl slowly and clump into clots; a clot lodging in the hind-leg arteries is ATE — this disease's most feared emergency. Clopidogrel blunts platelet clumping to lower those odds, and the feline randomized FAT CAT trial proved it beats aspirin at preventing recurrence. Hence the ACVIM recommendation to start prevention at stage B2. The fact-check article tells the full story.
Irreplaceable once breathing difficulty (stage C) begins. Never stop it over kidney worries on your own — dose-tuning is a tug-of-war to run with your vet.
Heart failure floods the lungs with fluid (pulmonary edema); diuretics pull that water out through urine and make breathing possible again — the backbone of stage C care. The power has a price: less body water means less renal blood flow, so creatinine and BUN rise and potassium drains. Management is about the lowest effective dose balancing "comfortable breathing" against "kidney numbers." Home-counted sleeping breaths are the best gauge of whether it is working — read alongside the breathing-rate card in Care Companion.
For cats in heart failure (stage C), the evidence for trying it is accumulating. But in obstructive HCM (HOCM) it can do harm — this is a drug prescribed by echo findings.
It strengthens contraction and dilates vessels — in dogs, a proven life-extender for heart failure. In cats it is off-label, with retrospective studies suggesting longer survival in CHF. One big string attached: in obstructive HCM (HOCM with SAM), boosting contraction can worsen the obstruction — the echocardiogram decides whether it is used at all. The textbook example of "not every heart drug helps every heart."
The "every HCM cat gets atenolol" era is over. It earns its place only in specific situations — very fast rates or significant outflow obstruction.
It slows the heart and cuts oxygen demand, and for years it was the default HCM prescription. But follow-up studies in asymptomatic cats failed to show slowed progression or longer life, and ACVIM 2020 no longer recommends blanket use. Its remaining role is narrow and clear: significant outflow obstruction (SAM), arrhythmias, or marked tachycardia. If your cat takes it, it is worth asking "why this drug for my cat?" at the next visit — not to stop it, but because knowing the reason is where good management starts.
The first attempt to slow the hypertrophy itself rather than manage symptoms. "Conditional approval" says it best — big hopes, held with careful confidence.
Every cardiac drug so far manages consequences — clots, congestion, obstruction. Rapamycin is the first aimed at the thickening process itself (the mTOR pathway). A small feline randomized trial (RAPACAT) signaled slowed wall-thickness progression, earning a weekly oral formulation US conditional approval (Felycin). The same stage as molidustat in our CKD compendium — promising, with large-scale proof still underway. The fact-check article covers the background.
Clearly worth starting when systolic stays above 160. For a cat with HCM, measuring blood pressure at diagnosis matters too — hypertension alone can thicken the heart walls and mimic HCM.
Hypertension has no symptoms, so unless it is measured it silently damages the eyes (sudden blindness), brain, heart and kidneys. In the heart, the left ventricular wall thickens to push against the higher pressure, which can look just like HCM — so pressure should be checked before HCM is diagnosed, and if it is high, treated first and the walls re-examined. Amlodipine is the feline standard that widens the vessels and lowers pressure quickly and reliably; telmisartan is licensed for cats. It is especially common in older HCM cats that also have hyperthyroidism or CKD, so home blood-pressure records become the basis for starting and dosing.
There is reason to give it — a randomised study of a diet with added omega-3 saw thinner heart walls and lower troponin. But the difference from controls was not clear-cut and the whole diet changed, so adding omega-3 alone should not be expected to do the same. It matters more once heart failure starts costing appetite and muscle.
The most direct evidence in HCM cats is a 2020 randomised, double-blind study. 44 cats with subclinical HCM were split between two diets for 12 months: the test diet cut starch to 39 g per 1000 kcal (control 113 g), raised protein to 125 g (control 64 g) and added 0.6 g of EPA+DHA (control 0.02 g). In the test group median wall thickness fell by 0.7–0.8 mm, cardiac troponin I and IGF-1 fell, and 30% of cats returned to normal wall thickness (6 mm or less) versus 14% of controls. However, control medians also fell (septum 0.6 mm, free wall 0.3 mm), and comparing the two groups directly, there was no significant difference at any time point. The effect was smaller in cats whose left atrium was already enlarged. Starch, protein and omega-3 changed together, so omega-3's share cannot be separated, and the study was funded by Royal Canin — hence a yellow grade. No dose study exists for cats with heart disease, so start from the canine heart-disease dose of EPA 40 mg + DHA 25 mg per kg (about 65 mg a day; 260 mg for a 4 kg cat). The dry test diet above supplied about 30 mg/kg a day. Feline platelet studies are mixed (no change with purified EPA and DHA; a change when the diet's fatty-acid balance was altered), so this is not a clot preventive — that is clopidogrel's job. In dogs with heart failure, fish oil lowered inflammatory signals and slowed muscle loss (cardiac cachexia), so it matters more once appetite and weight start to slip. A human single-ingredient product is fine; dose by combined EPA+DHA and keep it refrigerated against rancidity.
A sure thing for a confirmed deficiency — but HCM is not caused by taurine shortage. For a cat on commercial food, there is no basis to expect benefit from extra.
Taurine owns feline nutrition's greatest success story — in 1987, taurine deficiency was identified as the cause of dilated cardiomyopathy (DCM), food was fortified, and DCM collapsed. That made it the iconic "heart supplement." The catch: that legend belongs to DCM (a dilating disease); HCM (a thickening disease) has nothing to do with taurine deficiency. Commercial diets already contain plenty, and extra has no demonstrated benefit. Cats on raw or home-cooked diets are the separate, legitimate deficiency question.
Not an evidence-based choice for HCM. Sold alongside taurine and ubiquinol as "good for the heart" — with the thinnest evidence of the three.
Carnitine shuttles fatty acids into the heart muscle's mitochondria, so "fuel supplement for the heart" sounds plausible. Some dogs with DCM showed carnitine-deficiency links and supplementation responses — and that story migrated into cat heart-supplement marketing. The bridge is broken twice: different species (dog→cat) and different disease (DCM, a dilating disease → HCM, a thickening one). No study shows carnitine helping feline HCM. Where carnitine genuinely appears in cats is hepatic lipidosis support — a liver story, not a heart one. It is also an ingredient in heart blends (e.g. Thorne-style combos), so use this entry when judging those.
One of the rare herbs with real human clinical trials — whose effect faded as the studies grew. No feline evidence.
Hawthorn is an exception among herbs — it carries not just tradition but actual human trial data. Early small studies and a 2008 Cochrane review suggested modest benefit as an adjunct in chronic heart failure. Then the biggest and longest trial, SPICE (2,681 patients, 2 years), failed to improve the combined outcome of death and hospitalization. Promising while small, fading at scale — the classic supplement-research trajectory.
And all of this is human chronic heart failure. Feline HCM is a disease of a thickened heart, not a weakened one — a different mechanism — and there is not a single cat study.
Three thousand years of tradition is real — but the length of a tradition is not the strength of its evidence. For cats there isn't even safety data.
The bark of the Terminalia arjuna tree, a flagship heart remedy in Ayurveda for nearly three millennia. A handful of small human trials exist, some reporting benefit — but their size and design have kept arjuna out of every mainstream cardiology guideline.
Cats are one step further removed: before efficacy, there is simply no metabolism or safety data. A small amount inside a blend is unlikely to harm — but this ingredient should not be what justifies a product's price or your hopes.
It wears the label "helps the body adapt to stress" — a category that science has never actually established. The link to the heart is even more distant.
Eleuthero is an "adaptogen" — a class of ingredients said to help the body adapt to stress. The catch: that class itself has never been clinically established. A vague definition makes it a convenient word — anything can join, and anything can be claimed.
There is no heart-specific evidence even in humans. It appears in cardiac blends not because of effect data but because of its traditional "general vitality" image. When you spot this name on a label, count it as one hint that the formula was assembled by image rather than evidence.
The flashiest ingredient in a test tube is not necessarily so inside a body. Cats in particular process plant compounds through different detox pathways than we do — so before efficacy, the missing piece is safety data.
Quercetin, the flavonoid in onions and apples, is a fixture of test-tube antioxidant research. Its weakness is poor absorption when eaten — hence delivery tech like phytosomes (phospholipid complexes), the form used in this product. In humans the evidence sits at small blood-pressure studies.
For cats there is a separate point worth remembering: cats are innately deficient in glucuronidation, a detox pathway (the same reason a fever drug that's safe for humans is lethal to cats). Many plant flavonoids are processed through exactly that pathway — so for cats, the first question about quercetin isn't "does it work" but "has a safe dose been established." The answer, so far, is no.
Vitamin E that corrects a deficiency is real medicine (pansteatitis). Vitamin E as "antioxidant heart protection" is a story large human trials have already answered — with a no.
Feline vitamin E deficiency is a real disease — pansteatitis, seen with oily-fish-heavy diets, and it is cured by vitamin E. That much is established medicine.
But the hope that "an antioxidant must protect the heart" carries the opposite history: human trials of thousands to tens of thousands of participants (HOPE 2000 and others) found no cardiovascular benefit, and a 2005 meta-analysis of high doses even signaled increased mortality. It is the textbook case of the antioxidant boom collapsing under large-scale testing.
Shines when filling a deficiency, loses its evidence when stacked on top — the pattern running through this whole compendium, in its clearest form.
The theory and human data are interesting, but there is not yet evidence of benefit in cats. Safety appears good.
A component of cellular energy production and an antioxidant. Some positive human heart-failure data made it popular for cardiac and senior support, but feline clinical evidence does not exist. In a senior cat already juggling pills, "adding one more harmless thing" is not always the right answer — pill stress is a cost too.
The SOD your cat's body makes matters greatly — but there is no evidence the SOD you feed does that job. A textbook case of marketing borrowing science's name.
SOD is the cell's first-line enzyme against free radicals — its role inside the body is genuine, important science. The problem is *eating* it: SOD is a protein enzyme, and swallowed proteins get broken down by stomach acid and digestive enzymes into amino acids. It never reaches the bloodstream as a working enzyme. Coated products (GliSODin etc.) try to dodge this, but the evidence is rodent-and-small-human-study level — and zero in cats.
One principle to keep: this applies to "edible enzymes" in general, with one exception — digestive enzymes (pancreatin etc.) are *meant* to work inside the gut, no bloodstream required. Those are the enzymes worth swallowing.
This compendium summarizes published research and anonymous app statistics for reference. Always discuss starting, stopping or dosing with your vet.
